EZH2 and cancer: Because SHR2554 is a novel, highly effective, and selective oral EZH2 inhibitor that may be frequently used in malignant tumors in the future, we hope that the results here will help researchers design and conduct future phase II/III studies and be good for clinical use and promotion of SHR2554.